Abstract

The number of COVID-19-associated nephropathies (COVAN) rapidly increased before the fourth wave of the COVID-19 pandemic. Similarities and common lesions with the HIV-associated nephropathy (HIVAN) remarkably affect mostly African Americans positive for the APOL1 risk variants; therefore, these cases must be prioritized in new targeted clinical trials.

Keywords: Cyclin-dependent kinase inhibitors, HIV-1, HAART, Polymorphism, HIVAN, COVAN, Glomerulosclerosis.
Fulltext HTML PDF ePub
1800
1801
1802
1803
1804